Menu Search
Equities

Oxford Biomedica PLC

OXBDF:PKC

Oxford Biomedica PLC

Actions
  • Price (USD)5.41
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change+105.72%
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024 16:07 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.

  • Revenue in GBP (TTM)97.28m
  • Net income in GBP-142.02m
  • Incorporated1996
  • Employees834.00
  • Location
    Oxford Biomedica PLCWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
  • Phone+44 186 578 3000
  • Fax+44 186 578 3001
  • Websitehttps://www.oxb.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.